Business UpdateJun 4, 2026, 04:24 PM
Sanara MedTech Terminates Advisory Agreement with Catalyst Group
AI Summary
Sanara MedTech Inc. has terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective June 2, 2026. This decision aligns with Sanara's new strategy to concentrate on soft tissue repair and bone fusion products for the surgical market. The company incurred no fees or penalties for the termination, though certain covenants like indemnification and confidentiality will remain active. Notably, Sanara's Chairman, Ronald T. Nixon, is the founder of Catalyst, which, along with its affiliates, holds more than 5% of Sanara's common stock.
Key Highlights
- Sanara MedTech terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc.
- The termination was effective immediately on June 2, 2026.
- The reason for termination is Sanara's strategic shift to focus on soft tissue repair and bone fusion products.
- No fee or penalty was paid by Sanara MedTech in connection with the termination.
- Certain covenants, including indemnification and confidentiality, from the original agreement remain in effect.
- Sanara's Chairman, Ronald T. Nixon, is the founder and managing partner of Catalyst.
- Catalyst and its affiliates collectively beneficially own over 5% of Sanara's outstanding common stock.
Price Impact
More from SMTI